Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UGT8 | Q16880 | 16/20 | 0.54 |
| ▸ | RBP4 | P02753 | 2/20 | 0.35 |
| ▸ | TTR | P02766 | 1/20 | 0.35 |
| ▸ | LIPC | P11150 | 1/20 | 0.34 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.34 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21813597 | 1.00 | UGT8 (0.54) | UGT8RBP4TTRLIPCLIPG | |
| SCHEMBL21862454 | 0.92 | UGT8 (0.65) | UGT8 | |
| SCHEMBL21862398 | 0.80 | UGT8 (0.73) | UGT8 | |
| SCHEMBL21813779 | 0.73 | UGT8 (0.63) | UGT8 | |
| SCHEMBL21813775 | 0.73 | UGT8 (0.63) | UGT8 | |
| SCHEMBL29233735 | 0.73 | UGT8 (0.48) | UGT8LIPCLIPGCCNE1CDK2 | |
| SCHEMBL21862438 | 0.70 | UGT8 (1.00) | UGT8 | |
| SCHEMBL30686905 | 0.70 | UGT8 (1.00) | UGT8 | |
| SCHEMBL21862452 | 0.70 | UGT8 (1.00) | UGT8 | |
| SCHEMBL21813578 | 0.68 | UGT8 (0.67) | UGT8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200102324-A1 | UDP GLYCOSYLTRANSFERASE INHIBITORS AND METHODS OF USE | GENZYME CORPORATION | 2020-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200102324-A1 | UDP GLYCOSYLTRANSFERASE INHIBITORS AND METHODS OF USE | MAN2B1, GAA, GBA1 | UGT8 74/4885RBP4 3894/4885TTR 3093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.